Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
about
Review and uses of stereotactic body radiation therapy for oligometastasesStereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancerComplications from Stereotactic Body Radiotherapy for Lung CancerChallenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?Stereotactic Body Radiotherapy in the Management of Oligometastatic DiseaseDosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastasesCritical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapySpecific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review.Normal tissue toxicity after small field hypofractionated stereotactic body radiation.Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity.Four-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer: a comparative planning study.From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.Design, development of water tank-type lung phantom and dosimetric verification in institutions participating in a phase I study of stereotactic body radiation therapy in patients with T2N0M0 non-small cell lung cancer: Japan Clinical Oncology GroupNo clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries.(18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy.Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors.Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study.Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveDosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiationClinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules.Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinomaPredictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy.Radiation dose-volume effects in the esophagusSignificance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastases.Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lungDelayed esophageal perforation from stereotactic body radiation therapy for locally recurrent central nonsmall cell lung cancer.A contemporary review of stereotactic radiotherapy: inherent dosimetric complexities and the potential for detriment.Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery?New concepts and insights into the role of radiation therapy in extracranial metastatic disease.Stereotactic body radiotherapy for early stage lung cancer.What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer.The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastaPredicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.Assessing the Need for Adjuvant Chemotherapy After Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Carcinoma.Clinical results of accelerated hypofractionated radiotherapy for central-type small lung tumours.Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors.
P2860
Q26864247-897843D4-4EC9-4BBA-9923-05810E04E97FQ26866335-BE49250C-298D-43A1-8ADF-47C3E330B4CFQ26995851-255C3C72-FA36-4A46-AC62-4FAFAC31FF6CQ27301421-7391E4B1-13F5-4C67-854C-289DEC45450FQ28071733-A550AFE8-AE9B-4ECD-BE45-37DFFAEC0052Q28730322-D6BAF369-B060-4100-8DCF-6ADD6BF9545BQ28950857-661FEA0E-9B8D-4824-9478-42F7C86F7BDDQ30241812-A783CE86-3C08-45D3-B0DE-E92BB667B757Q30484881-E0A087F6-707C-435E-9944-ED1A236081F2Q33305385-A96006EF-BABA-48AF-9175-CA0791DB5CD7Q33315026-C2B965B8-785F-4D80-A656-09BB0AAB51B5Q33378130-DA2087BC-1EF8-44A9-B81D-CB9A1B1F77E3Q33582628-54BF02FF-07FE-466B-B6AF-9BA80DE63090Q33758565-DC803AFB-11ED-4FBA-870E-AC63EAE3D105Q33907089-2183F607-F6FF-4F47-ABCB-13D8466E2EE1Q33973399-09098583-0BA1-404A-97F5-DBB013FF711BQ34623353-6926273C-96BB-4C67-AA81-4763DB20C6ABQ35599955-8D1CE4FA-FB7E-4287-A07C-1F29E5DB9629Q35646076-122C0960-8907-427D-9C62-1A3C7C97A75BQ35846913-91F60175-7D3A-48D6-AAB4-3969EB414E88Q36235727-5E7E5F1A-0A66-4852-8695-1855761BCA8AQ36451644-3C6215ED-02FD-4A3B-A3FB-CD6EE8BA9F00Q36481633-5F739599-F30B-4753-8A65-1F2DE15FB7AAQ36496500-1A69A9A6-2D26-4394-A24D-A4A06B7917E1Q36500564-B18D881B-CF02-485F-8A8B-06CD2933345AQ36655289-2FEF5573-F6E9-4BD7-B893-BA32D94ABD9FQ37450582-F70FEA74-C753-4086-BF66-D98A04C1C1B4Q37670425-62B210C2-F0DE-44B2-B40F-618A320148EEQ37723351-F18E572F-91BC-4223-AB72-F12D1A809DA5Q37834640-E624FA89-F65F-4608-B682-91A30BA6EC6BQ38051243-5DC4CC75-8F0B-4563-B284-452ED377AD40Q38153442-D50F8E8D-4AA7-46ED-92D9-06808C541D14Q38155155-C7A8DD37-984E-4E88-8202-E54C05B80A8FQ38172228-43B522C3-A0EC-436B-A570-F86597E1EB43Q38227883-0C2B75B4-A9F2-4075-9CA6-5A5DB82A4CECQ38757792-7FB6B402-88DE-4B98-BDE5-96CC76BA9E4EQ39015830-1D388E37-97EA-4F6A-9568-12EC3DBEFDA7Q40608540-CCA929FE-CCBB-4E42-81E7-C8DB7183215AQ41559497-84D6DEE0-394D-4CF4-8C67-DC0A78D15A15Q42321832-38CBAA31-FAA9-49B4-A8B6-20B253FFD19C
P2860
Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tolerance of organs at risk in ...... y and metastatic lung cancers.
@ast
Tolerance of organs at risk in ...... y and metastatic lung cancers.
@en
type
label
Tolerance of organs at risk in ...... y and metastatic lung cancers.
@ast
Tolerance of organs at risk in ...... y and metastatic lung cancers.
@en
prefLabel
Tolerance of organs at risk in ...... y and metastatic lung cancers.
@ast
Tolerance of organs at risk in ...... y and metastatic lung cancers.
@en
P2093
P1476
Tolerance of organs at risk in ...... ry and metastatic lung cancers
@en
P2093
Hiroki Shirato
Hirotoshi Dosaka-Akita
Katsuhisa Fujita
Kazuo Miyasaka
Kei Kitamura
Masataka Oita
Rikiya Onimaru
Shin-ichi Fukumoto
Shinichi Shimizu
P304
P356
10.1016/S0360-3016(03)00095-6
P407
P577
2003-05-01T00:00:00Z